INFIQ: AI 评分 62/100 — AI 分析 (4月 2026)

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments. The company filed for Chapter 11 bankruptcy in 2023 and is currently undergoing liquidation.

Key Facts: AI Score: 62/100 Sector: Healthcare

公司概况

概要：

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that was focused on developing novel cancer medicines, including eganelisib (IPI-549). The company filed for Chapter 11 bankruptcy in September 2023 and is currently undergoing liquidation, impacting its future prospects and operations within the biotechnology sector.

INFIQ是做什么的？

Founded in 1995 and headquartered in Cambridge, Massachusetts, Infinity Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company dedicated to discovering, developing, and delivering novel cancer treatments. The company's primary focus was on immuno-oncology product candidates, with its lead product candidate being eganelisib (IPI-549), an orally administered inhibitor of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Eganelisib was in Phase 2 clinical trials for metastatic triple-negative breast cancer and urothelial cancer, as well as Phase 1/1b trials for solid tumors. Infinity Pharmaceuticals pursued strategic alliances to expand its research and development capabilities. These included collaborations with Intellikine, Inc. (targeting PI3K delta and gamma isoforms), Verastem, Inc. (duvelisib), PellePharm, Inc. (IPI-926 hedgehog inhibitor program), F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. These partnerships aimed to accelerate the development and commercialization of innovative cancer therapies. However, on September 29, 2023, Infinity Pharmaceuticals and its affiliate filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on March 7, 2024, signaling a significant shift in the company's operational status.

INFIQ的投资论点是什么？

Infinity Pharmaceuticals' Chapter 11 liquidation significantly alters its investment profile. The company's prior focus on eganelisib (IPI-549) and strategic alliances with companies like Verastem and Bristol Myers Squibb are now secondary to the bankruptcy proceedings. Key value drivers related to clinical trial outcomes and potential drug approvals are now defunct. Potential catalysts related to clinical data releases or partnership expansions are no longer relevant. The primary risk factor is the uncertainty surrounding the liquidation process and potential recovery for stakeholders. Investors should carefully consider the implications of the Chapter 11 liquidation before making any decisions regarding INFIQ.

INFIQ在哪个行业运营？

Infinity Pharmaceuticals operated within the competitive biotechnology industry, characterized by high research and development costs, lengthy clinical trial processes, and regulatory hurdles. The industry is driven by innovation and the development of novel therapies for unmet medical needs. Companies like Infinity Pharmaceuticals often rely on strategic alliances and partnerships to share costs and accelerate drug development. However, the company's Chapter 11 liquidation reflects the inherent risks and challenges in the biotechnology sector, including clinical trial failures, funding constraints, and market competition.

Biotechnology

Healthcare

INFIQ有哪些增长机遇？

Growth opportunity 1: Not applicable. Given the Chapter 11 liquidation, Infinity Pharmaceuticals no longer has viable growth opportunities related to its previous clinical programs or strategic alliances. The company's assets are being liquidated, and its operations are ceasing.
Growth opportunity 2: Not applicable. There are no growth opportunities for Infinity Pharmaceuticals due to the Chapter 11 liquidation.
Growth opportunity 3: Not applicable. The company's bankruptcy eliminates any potential for future growth.
Growth opportunity 4: Not applicable. Infinity Pharmaceuticals is in liquidation, so there are no growth opportunities.
Growth opportunity 5: Not applicable. The company's situation precludes any growth prospects.

Market capitalization is $0.00B, reflecting the company's distressed financial state.
Free cash flow is negative ($-0.00B), indicating the company's inability to generate positive cash flow from operations.
Beta is 9.38, suggesting very high volatility compared to the overall market.
No dividend is paid, reflecting the company's financial constraints.
Chapter 11 liquidation approved on March 7, 2024, marking a significant turning point for the company.

INFIQ提供哪些产品和服务？

Focused on developing novel medicines for cancer treatment.
Developed eganelisib (IPI-549), an immuno-oncology product candidate.
Conducted Phase 2 clinical trials for metastatic triple negative breast cancer and urothelial cancer.
Conducted Phase 1/1b clinical trials for solid tumors.
Formed strategic alliances with Intellikine, Inc., Verastem, Inc., and PellePharm, Inc.
Collaborated with F. Hoffmann-La Roche Ltd. and Bristol Myers Squibb Company.
Filed for Chapter 11 bankruptcy in September 2023.
Undergoing Chapter 11 liquidation as of March 2024.

INFIQ如何赚钱？

Historically, Infinity Pharmaceuticals focused on developing and out-licensing or commercializing novel cancer therapies.
The company relied on strategic alliances and collaborations to fund research and development.
The company's business model is now centered on the liquidation of its assets to satisfy creditors.

Historically, potential customers included patients with cancer and healthcare providers.
Pharmaceutical companies were also customers through licensing and collaboration agreements.
Currently, the company's primary customers are creditors and stakeholders involved in the bankruptcy proceedings.

Historically, intellectual property rights and patents related to its drug candidates provided a potential moat.
Strategic alliances with larger pharmaceutical companies offered a competitive advantage.
The company's current moat is non-existent due to the Chapter 11 liquidation.

什么因素可能推动INFIQ股价上涨？

Upcoming: Not applicable due to liquidation.
Ongoing: Chapter 11 liquidation proceedings.

INFIQ的主要风险是什么？

Potential: Limited or no recovery for shareholders in the liquidation process.
Ongoing: Uncertainty surrounding the timeline and outcome of the bankruptcy proceedings.
Potential: Delisting from the OTC market.
Potential: Legal challenges or disputes related to the liquidation.
Ongoing: High volatility and speculative trading activity.

INFIQ的核心优势是什么？

Historically, a focus on immuno-oncology and targeted therapies.
Strategic alliances with established pharmaceutical companies.
Experienced management team (prior to bankruptcy).

INFIQ的劣势是什么？

Chapter 11 bankruptcy and liquidation.
Lack of revenue-generating products.
High cash burn rate.

INFIQ有哪些机遇？

Not applicable due to liquidation.

INFIQ面临哪些威胁？

Uncertainty surrounding the liquidation process.
Potential for limited recovery for stakeholders.
Loss of intellectual property and assets.

INFIQ的竞争对手是谁？

Verastem, Inc. — Focuses on developing and commercializing drugs to improve the survival and quality of life of cancer patients. — (VSTM)

Key Metrics

MoonshotScore: 62/100

Company Profile

Headquarters: Cambridge, United States
Employees: 30

AI Insight

AI analysis pending for INFIQ

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Infinity Pharmaceuticals, Inc. do?

Infinity Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on discovering and developing novel cancer medicines. Its lead product candidate, eganelisib (IPI-549), was in clinical trials for various cancer types. The company also pursued strategic alliances with other pharmaceutical companies to expand its research and development efforts. However, the company filed for Chapter 11 bankruptcy in September 2023 and is currently undergoing liquidation, effectively ceasing its operations and development programs. The company's assets are being liquidated to satisfy creditors.

What do analysts say about INFIQ stock?

Given Infinity Pharmaceuticals' Chapter 11 bankruptcy and liquidation, traditional analyst ratings and price targets are no longer relevant. The company's financial metrics, such as revenue growth and earnings per share, are not indicative of its future performance. Any remaining trading activity in INFIQ stock is highly speculative and driven by factors unrelated to the company's underlying business. Investors should exercise extreme caution and understand the risks associated with trading bankrupt or distressed securities.

What are the main risks for INFIQ?

The primary risk for INFIQ is the Chapter 11 liquidation, which means the company's assets are being sold off to pay creditors. Shareholders are typically the last to receive any proceeds in a liquidation, and there is a high likelihood that they will receive little to no recovery on their investment. Other risks include delisting from the OTC market, legal challenges related to the bankruptcy proceedings, and the potential for further losses due to speculative trading activity. Investing in INFIQ at this stage is highly speculative and carries a significant risk of complete loss.